Myelodysplastic Syndrome Market - Forecast(2024 - 2030)

Key Takeaways

• The North America region has been estimated to hold the largest share owing to the increased awareness as well as increased expenditure for health. Information on other major regions given in full myelodysplastic syndrome market report.
• The rise in the overall geriatric population globally is set to drive the market. Other major growth drivers mentioned in full myelodysplastic syndrome market report.
• The high treatment cost is considered as a challenge for the market growth. Other major challenges that has influence over the market mentioned in the full myelodysplastic syndrome market report.

Drug Class - Segment Analysis

The immunomodulatory drug class is estimated to hold the largest share in this segment. This is a drug class that is used in chemotherapy and is used for people with chromosomal abnormalities. However, the Hypomethylating drugs segment is estimated to have the largest CAGR of 8.64% during the forecast period owing to its increased use.

Geography - Segment Analysis

The North America region has been estimated to hold the dominance with myelodysplastic syndrome market share of 46.2%. This is owing to the high health expenditure cost as well as increased awareness regarding the disease and the easy availability of treatment options. However, the APAC region is estimated to have the highest CAGR during the forecast period. This is due to the rapid urbanization of Asian Countries as well as a rapid growth rate of the geriatric population. In the APAC region, Japan is set to hold the highest growth rate.

Drivers – Myelodysplastic Syndrome Market

·         Rising Geriatric Population

There is an overall increase in the geriatric population in the world. Studies has shown that the prevalence of myelodysplastic syndrome increases in elderly population and they are more likely to seek for treatment. This factor could be considered as a major market driver.

·         Government Support

The various government initiatives that provide target specific treatment as well as favorable reimbursement policies are estimated to fuel the overall myelodysplastic syndrome market. The government initiatives can also rise the overall awareness of the people.

Challenges – Myelodysplastic Syndrome Market

·         High Treatment cost

The treatment for myelodysplastic syndrome requires huge capital input. Also, other risks associated with the treatment are present which can make the people reluctant to obtain the treatment. This factor has the potential to limit the overall market growth.

Myelodysplastic Syndrome Industry Outlook

Partnerships and Product Launches are the key strategies employed by the major players of this market. Myelodysplastic Syndrome top 10 companies include: Celgene Corporation, Cipla, Inc., Dr. Reddy’s Laboratories Ltd., Hikma Pharmaceuticals PLC, Johnson & Johnson, Lupin Ltd., Otsuka Pharmaceutical Co., Ltd., Pfizer, Inc., Amgen Inc. and Takeda Pharmaceutical Company Limited., among others.

Partnerships/Product Launches

• On January 2015, Amgen and MD Anderson Cancer Center had announced an agreement for developing BiTE therapies for Myelodysplastic syndrome. This collaboration will call on the use of the MD Anderson Cancer Centre’s Moon Shots Program that aims to convert scientific discoveries into clinical advances at a much faster rate.
• On March 2017, Janssen-Cilag International N.V.(Johnson & Johnson) had announced that the product named “EPREX”for the treatment of symptomatic anemia for myelodysplastic syndrome has been approved for marketing by the French Authority Agence Nationale de Sécurité du Médicament et des Produits de Santé